THR Beta Agonist Intermediate Synthesis Without Chiral Separation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing methods for preparing a selective THR beta agonist suffer from poor intermediate stability, difficult purification, high cost, and limitations in large-scale production due to the need for chiral separation methods like SFC, leading to low yield and restricted supply.
Innovation Solution
A new synthetic route for the intermediate (II) using palladium catalysts, specific ligands, and bases in various solvents, eliminating the need for chiral separation and incorporating simple and efficient processes with inexpensive raw materials.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If chiral separation methods such as SFC are used for intermediate preparation, then optical purity is improved, but production cost increases and productivity decreases
Solution Approach 1:
The patent employs chiral pool strategy by selecting chiral starting materials with predetermined stereochemistry, performing chiral modification reactions early in the synthesis route to establish the desired stereoconfiguration before subsequent steps, thereby avoiding the need for chiral separation methods like SFC and enabling scalable production
2Manufacturing precision
If chiral separation methods such as SFC are used for intermediate preparation, then optical purity is improved, but manufacturing cost increases
Solution Approach 1:
The patent employs chiral pool strategy by selecting chiral starting materials with predetermined stereochemistry, performing chiral modification reactions early in the synthesis route to establish the desired stereoconfiguration before subsequent steps, thereby avoiding the need for chiral separation methods like SFC and enabling scalable production
Solution Approach 2:
The patent uses commercially available chiral starting materials and standard chiral reagents that are inexpensive and readily accessible, replacing expensive specialized chiral separation equipment and processes with affordable chemical methods
3Ease of manufacture
If existing preparation methods are used, then the synthesis route is established, but intermediate stability deteriorates and purification difficulty increases
Solution Approach 1:
The patent optimizes reaction parameters including temperature control, solvent selection, and reaction time to improve intermediate stability, and modifies purification parameters such as chromatography conditions to facilitate easier separation and purification of intermediates
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new route enables easy scale-up production with controllable quality and cost, improving yield and making industrial application feasible.
Implementation Method 1
coupling an intermediate represented by formula (III) with a compound represented by formula (C) under nitrogen atmosphere in the presence of a palladium catalyst, a ligand, a base, and a solvent under heating or at room temperature to obtain a compound represented by formula (B)
Data Source
AI summary
The present invention provides a method for synthesizing a key intermediate compound represented by formula (II) of a selective THR beta agonist. Raw materials used in the method are inexpensive and readily available, the process is simple and efficient, no SFC chiral separation is required, the yield is high, quality and costs are controllable, and the method has great industrial prospects.